Tesla's retro-futuristic diner officially opens as Elon Musk hints at more locations
The Tesla Diner & Drive-In is technically a place for Tesla drivers to charge their EVs and maybe get hamburger, hot dog, or other classic diner menu items (which Eater shared in full). The diner, which per reporting from Not a Tesla App is loaded with Tesla-branded merchandise, an Optimus robot, and two 45-foot LED movie screens, is clearly hoping to attract more than just Tesla owners.
It's too early to tell if the diner, which boasts 80 v4 Superchargers stalls and a drive-in movie theater that syncs with speakers inside a driver's Tesla, will become an enduring fixture of Hollywood. The long lines of people who queued up Monday morning suggests the diner will attract crowds for awhile.
Even before its doors officially opened, Tesla CEO Elon Musk mused about establishing more of the diners globally.
'If our retro-futuristic diner turns out well, which I think it will, @Tesla will establish these in major cities around the world, as well as at Supercharger sites on long distance routes,' Musk posted on X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
MLB Speedway Classic between Braves and Reds set to break attendance record
Major League Baseball will soon see one of its highest-attended games ever on August 2. MLB announced that the Speedway Classic, featuring the Atlanta Braves vs. the Cincinnati Reds, at Bristol Motor Speedway in Tennessee, has already sold over 85,000 tickets. The game is set to surpass the previous regular-season game attendance record of 84,587, established on Sept. 12, 1954, when Cleveland Stadium hosted the New York Yankees. August 2 will not only feature the game, but also concerts headlined by Jake Owen, Tim McGraw, and Pitbull. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] It will also be the first MLB game ever in the state of Tennessee. The first pitch will be between two Hall of Famers: The Braves' Chipper Jones will pitch to the Reds' Johnny Bench. The all-time attendance record was set during an exhibition game between the Los Angeles Dodgers and Boston Red Sox on March 29, 2008, at the Los Angeles Memorial Coliseum, with 115,300 fans in attendance. TRENDING STORIES: Walton County family sues after home sold using forged deed PHOTOS: Best 25 public middle schools in Georgia Geo-fencing technology leads to arrest in 71-year-old grandmother's cold case murder [SIGN UP: WSB-TV Daily Headlines Newsletter]
Yahoo
a few seconds ago
- Yahoo
Rambus Inc (RMBS) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth in AI ...
Revenue: $172.2 million for Q2, exceeding expectations. Product Revenue: $81.3 million, marking a 7% sequential increase and 43% year-over-year growth. Royalty Revenue: $68.6 million. Licensing Billings: $66.4 million. Cash from Operations: Record $94 million. Operating Costs: Total operating costs, including COGS, were $93.2 million. Operating Expenses: $60.4 million. Non-GAAP Net Income: $67.1 million. Cash Equivalents and Marketable Securities: $594.8 million at quarter-end. Capital Expenditures: $10.4 million. Depreciation Expense: $7.4 million. Free Cash Flow: $84 million. Q3 Revenue Guidance: Expected between $172 million and $178 million. Q3 Non-GAAP Earnings Per Share Guidance: Expected between $0.58 and $0.66. Warning! GuruFocus has detected 4 Warning Sign with RMBS. Release Date: July 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Rambus Inc (NASDAQ:RMBS) delivered a strong second quarter, exceeding expectations for both revenue and earnings. The memory interface chip business experienced a 43% year-over-year growth, contributing to record product revenue. The company generated record cash from operations of $94 million, showcasing efficient execution and a robust business model. Rambus Inc (NASDAQ:RMBS) has a balanced portfolio and diverse revenue streams across chips, silicon IP, and patent licensing, providing stability in a dynamic market. The company is strategically focused on advancing system memory bandwidth and capacity, aligning with long-term growth trends in AI and high-performance computing. Negative Points The contribution from new chips, including power management chips, is still modest, representing low single-digit percentages of product revenue. The economic environment remains dynamic, posing potential risks to future financial performance. Inventory levels are lean, which could pose challenges if demand surges unexpectedly. The market for DDR4 is declining, and while DDR5 is growing, the transition may not be seamless. The timeline for significant revenue contributions from new products, such as MRDIMM, is projected for the second half of 2026, indicating a delay in realizing potential growth. Q & A Highlights Q: How do you view the contribution from RCDs and the ramp of the PMIC opportunity in your product revenue growth? A: Luc Seraphin, CEO: We are pleased with our product business growth, with a 43% year-over-year increase in Q2. RCD remains strong, and we continue to gain market share with DDR5 expansion. We were slightly above 40% share at the end of 2024 and expect to continue gaining share. New chips, including power management chips, are contributing modestly but show momentum. We expect further demand as platforms transition from 12 to 16 channels. Q: Can you provide visibility into PMIC sales in the PC market and any client co-driver revenue? A: Luc Seraphin, CEO: We see high-end PC market requirements similar to data centers, leading to the introduction of clock drivers and PMIC products. We expect modest traction initially, with contributions visible in 2026. This year, we will see initial shipments for qualification and pre-production orders. Q: How is the AI ASIC market affecting demand for your silicon IP? A: Luc Seraphin, CEO: The AI market's growth increases demand for high-speed connectivity and memory interfaces, accelerating development for solutions like HBM4 and PCIe 7. We have several engagements in these technologies, and the need for data security is boosting sales of our silicon IP in the security area. Q: What is the impact of DDR-4 end-of-life announcements on Rambus? A: Luc Seraphin, CEO: DDR4 sales remain limited, and we don't see significant changes. Inventories are decreasing, and we expect DDR4 to remain low, with potential case-by-case last-time buy orders. Q: How is the mix of product revenue evolving with the increased contribution from companion chips? A: Luc Seraphin, CEO: New products, mostly companion chips, contributed low single digits to product revenue in Q2, expected to rise to mid-to-upper single digits in Q3. We see strong momentum in adoption, and contributions will continue to increase towards year-end and into 2026. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
Ekso Bionics Holdings Inc (EKSO) Q2 2025 Earnings Call Highlights: Navigating Revenue Decline ...
Revenue: $2.1 million for Q2 2025, down from $5 million in Q2 2024. Gross Profit: $800,000 for Q2 2025, compared to $2.6 million in Q2 2024. Gross Margin: Approximately 40% for Q2 2025, down from 53% in Q2 2024. Operating Expenses: $4.8 million for Q2 2025, a 4% decrease from $5 million in Q2 2024. Net Loss: $2.7 million for Q2 2025, or $1.24 per share, compared to $2.4 million, or $1.99 per share, in Q2 2024. Cash and Restricted Cash: $5.2 million as of June 30, 2025. Personal Health Product Revenue Growth: More than 50% increase in the first half of 2025 compared to the same period in 2024. Warning! GuruFocus has detected 2 Warning Signs with EKSO. Release Date: July 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Ekso Bionics Holdings Inc (NASDAQ:EKSO) is confident in closing a significant portion of deferred multi-device Enterprise Health sales by year-end. The company has launched eksoUniversity, a virtual platform providing continuing education courses to physical therapists, which could generate incremental revenue. Personal Health product revenues grew by more than 50% year-over-year in the first half of 2025. Ekso Bionics Holdings Inc (NASDAQ:EKSO) has partnered with PRIA Healthcare to enhance market access and commercialization of the Ekso Indego Personal device. The company is leveraging AI capabilities through the NVIDIA Connect program to enhance its exoskeleton technology platforms. Negative Points Ekso Bionics Holdings Inc (NASDAQ:EKSO) experienced a significant revenue decline in Q2 2025, with revenues dropping to $2.1 million from $5 million in Q2 2024. Gross profit and gross margin decreased due to lower Enterprise Health device sales and increased shipping costs. The company reported a net loss of $2.7 million for Q2 2025, compared to a net loss of $2.4 million in Q2 2024. There are short-term delays in completing significant multi-device Enterprise Health sales, impacting revenue. A small percentage of US customers have delayed purchases due to loss of federal grants and economic uncertainties. Q & A Highlights Q: Can you quantify the deferred sales on the Enterprise Health side and how much you expect in the back half of the year? A: Scott Davis, CEO, explained that two multiunit device sales were delayed, one international order due to regulatory challenges expected to occur in 2025, and a North American IDN order expected in Q3, totaling about $1.4 million. Q: When do you expect the Indego Personal to overtake the Enterprise Health business? A: Scott Davis, CEO, indicated that while Indego Personal represented about 10% of revenue in 2024, it is expected to contribute closer to 25% in 2025. By 2027, it is anticipated to overtake the Enterprise Health business. Q: How is the process of nailing down the patient profile and claims for Indego Personal progressing? A: Scott Davis, CEO, noted progress in the appeals process, with positive outcomes reaffirming medical necessity. They are working with DME and O&P partners to ensure strong claims submissions, aiming for routine approvals. Q: Will eksoUniversity focus solely on exoskeletons, or will it include other content? A: Scott Davis, CEO, stated that while initial courses focus on exoskeleton technology, eksoUniversity will cover a wide range of neuro rehabilitation topics, leveraging contributions from neuro PTs within their ecosystem. Q: What steps are being taken to ensure growth in enterprise sales, and how long will it take? A: Scott Davis, CEO, mentioned that they are working to close deferred deals and exploring options like third-party financial partners to help customers with budget constraints. They are optimistic about pulling in deferred deals in Q3. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
